Pembrolizumab


Entry
D10574                      Drug                                   
Name
Pembrolizumab (USAN);
Pembrolizumab (genetical recombination) (JAN);
Keytruda (TN)
Product
KEYTRUDA (Merck Sharp & Dohme LLC)
Formula
C6504H10004N1716O2036S46
Exact mass
146195.918
Mol weight
146286.2902
Sequence
(Heavy chain)
QVQLVQSGVE VKKPGASVKV SCKASGYTFT NYYMYWVRQA PGQGLEWMGG INPSNGGTNF
NEKFKNRVTL TTDSSTTTAY MELKSLQFDD TAVYYCARRD YRFDMGFDYW GQGTTVTVSS
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG
NVFSCSVMHE ALHNHYTQKS LSLSLGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASKGVS TSGYSYLHWY QQKPGQAPRL LIYLASYLES
GVPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQHSRDLPL TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H96, H134-L218, H147-H203, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'134-L'218, H'147-H'203, H'261-H'321, H'367-H'425, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FF02
Product: D10574<JP/US>
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  Disease
Melanoma [DS:H00038]
Non-small cell lung cancer (PD-L1 expressed) [DS:H00014]
Small cell lung cancer [DS:H00013]
Head and neck squamous cell carcinoma (PD-L1 expressed) [DS:H02420]
Head and neck squamous cell carcinoma [DS:H02420]
Hodgkin lymphoma [DS:H00007]
Urothelial carcinoma (PD-L1 expressed) [DS:H00022]
Urothelial carcinoma [DS:H00022]
Solid tumor (MSI-H) [DS:H02421]
Colorectal cancer (MSI-H) [DS:H00020]
Gastric cancer (PD-L1 expressed) [DS:H00018]
Gastric cancer [DS:H00018]
Esophageal cancer (PD-L1 expressed) [DS:H00017]
Cervical cancer (PD-L1 expressed) [DS:H00030]
Hepatocellular carcinoma [DS:H00048]
Merkel cell carcinoma [DS:H01555]
Renal cell carcinoma [DS:H00021]
Endometrial carcinoma (MSI-H or dMMR) [DS:H00026]
Breast cancer (triple-negative, PD-L1 expressed) [DS:H00031]
Comment
Monoclonal antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF02 Pembrolizumab
      D10574  Pembrolizumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Pembrolizumab
    D10574  Pembrolizumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10574  Pembrolizumab (USAN); Pembrolizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10574  Pembrolizumab
Drug classes [BR:br08332]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D10574  Pembrolizumab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D10574  Pembrolizumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10574
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10574
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10574
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10574
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10574
Other DBs
CAS: 1374853-91-4
PubChem: 254741536